DeCure for Ehlers-Danlos syndrome, classic type, 1
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Ehlers-Danlos syndrome, classic type, 1 — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEhlers-Danlos syndrome, classic type, 1 maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ehlers-danlos syndrome, classic type, 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
collagen type I alpha 1 chain (COL1A1) — COL1A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet eladrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7E7B · 2.6 Å · ligand Elaidic acid (ELA). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Surgery · 1982 · 62 citations
Vascular Manifestations in Patients With Ehlers-Danlos Syndrome
AbstractEhlers-Danlos syndrome (EDS) is clinically and genetically a heterogenous disorder of connective tissue synthesis. Seven clinical types of this disease have been identified and the underlying biochemical defects defined in types IV through VII. Unfortunately, most patients with major vascular complications of EDS have few, if any of the commonly recognized musculoskeletal and cutaneous abnormalities. Recognition of the correct diagnosis and the application of accepted vascular surgical techniques may improve the morbidity and mortality for these patients.
Regional Anesthesia & Pain Medicine · 1997 · 10 citations
Anesthesia for cesarean delivery in a patient with ehlers-danlos syndrome type II
AbstractBACKGROUND AND OBJECTIVES: Ehlers-Danlos syndrome, an inherited connective tissue disease, is rarely seen in pregnancy. Presentation may be mild or severe, depending on which type of the syndrome the patient possesses. METHODS: A 38-year-old woman with Ehlers-Danlos syndrome type II presented for cesarean delivery at 34 weeks' gestation with premature rupture of membranes and breech presentation. RESULTS: A subarachnoid block was chosen to provide surgical anesthesia. No adverse side effects or complications developed. CONCLUSION: In patients with Ehlers-Danlos syndrome, it is important to be aware of which type is present and to be knowledgeable about and prepared for any potential complications.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
